# US 2025/0082637 A1 · Pharmaceutical compositions comprising 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)pi-perazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetate and potassium ions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082637 A1
- Document ID: US20250082637A1
- Status: Published application
- Kind: A1
- Application number: 18/722,433
- Filed: 2022-12-21
- Published: 2025-03-13
- Earliest claimed: 2021-12-21
- Assignees: AIC246 AG & Co. KG
- Applicants: Aic246 AG & Co. KG
- Inventors: Helmut BUSCHMANN; Thomas GOLDNER; Jordi Carles CERÓN BERTRAN
- Web page: https://patentgrep.com/patent/US20250082637A1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 47/02: Inorganic compounds
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61P 31/12: Antivirals
- A61P 31/22: for herpes viruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to new stable pharmaceutical compositions containing 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetic acid and potassium ions that are essentially free from complexing solubilizing agents, such as PEG, cyclodextrin, lysine, arginine, in particular HPBCD. The invention further relates to methods of preparation of said pharmaceutical compositions. The invention further relates to use of said pharmaceutical compositions in methods of treatment of and/or as a prophylactic for illnesses, particularly its use as an antiviral, preferably against cytomegaloviruses.

## Claims

### Claim 1

A pharmaceutical composition comprising letermovir of formula (I), and potassium ions
wherein the pharmaceutical composition
comprises the potassium ions in a molar ratio to letermovir in the range of from 0.80 to <1.00:1.00; and
is capable of exhibiting a pH in the range of from 7 to 8, when said pharmaceutical composition is dissolved in water in a concentration range of from 20 to 100 mg/mL with respect to letermovir; and
is essentially free from complexing solubilizing agents selected from the group consisting of PEG, lysine, arginine, a cyclodextrin, in particular a hydroxypropyl-beta-cyclodextrin (HPBCD).

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the potassium ions are contained in the form of a solution of potassium hydroxide (KOH).

### Claim 3 (depends on 1)

The pharmaceutical composition according to claim 1, further comprising at least one excipient selected from the group consisting of carbohydrates, amino acids, polyalkoxy compounds, and polyvinylpyrrolidones.

### Claim 4 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is essentially free from complexing solubilizing agents.

### Claim 5 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition comprises a polyalkoxy compound.

### Claim 6 (depends on 3)

The pharmaceutical composition according to claim 3, wherein the excipient is mannitol or sucrose or a combination thereof.

### Claim 7 (depends on 1)

The pharmaceutical composition according to claim 1, further comprising a buffer.

### Claim 8 (depends on 1)

A method of producing the pharmaceutical composition as defined in claim 1, comprising:
i) providing a solution of letermovir and potassium ions, wherein the molar ratio of potassium ions to letermovir is in the range of from 0.80 to <1.00:1.00, and optionally at least one excipient selected from carbohydrates, amino acids, polyalkoxy compounds, and polyvinylpyrrolidones (PVP),
ii) if needed adjusting the pH of the solution obtained in step i) to a range of from 7 to 8, and
iii) optionally filtering said solution.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the potassium ions are provided in step i in the form of a KOH solution.

### Claim 10 (depends on 9)

The method according to claim 9, further comprising the subsequent step of freeze-drying the obtained solution to provide a lyophilizate.

### Claim 11 (depends on 10)

The method according to claim 10, further comprising the subsequent step of reconstituting the lyophilizate in a first parenterally acceptable diluent to provide a reconstituted solution in a concentration range of from 20 to 100 mg/mL with respect to letermovir and optionally subsequently diluting said reconstituted solution with a second parenterally acceptable diluent to a final concentration which is acceptable for injection or infusion, wherein said first and said second parenterally acceptable diluents can be the same or different.

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14 (depends on 1)

A method of treatment and/or prevention of a virus infections, in a subject in need thereof wherein the method comprises administering the pharmaceutical composition as defined in claim 1.

### Claim 15 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the molar ratio of potassium ions to letermovir is in the range of from 0.88 to <1.00:1.00.

### Claim 16 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the molar ratio of potassium ions to letermovir is in the range of from 0.90 to <1.00:1.00.

### Claim 17 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the potassium ions are contained in the form of an aqueous solution of potassium hydroxide (KOH).

### Claim 18 (depends on 3)

The pharmaceutical composition according to claim 3, wherein said at least one excipient is selected from the sucrose, mannitol, phenylalanine, poloxamers, and polyvinylpyrrolidone PF12.

### Claim 19 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition comprises a poloxamer, and is essentially free from other complexing solubilizing agents.

### Claim 20 (depends on 1)

The pharmaceutical composition according to claim 1, further comprising tris hydroxy aminomethane.

### Claim 21 (depends on 14)

The method according to claim 14, wherein the virus infections is a human cytomegalovirus (HCMV) infection.

### Claim 22 (depends on 14)

The method according to claim 14, wherein the virus infections is an infection by a member of the herpes viridae group.
